SCHEMBL7605396

SCHEMBL7605396

O=P(O)(Cc1cccc2ccccc12)Oc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 2/20 0.63
TDP1 Q9NUW8 2/20 0.47
SRC P12931 1/20 0.46
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
CYP1A2 P05177 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 2/20 0.41
CTNNB1 P35222 1/20 0.41
FFAR1 O14842 1/20 0.41
AKR1B1 P15121 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PARP10 Q53GL7 1/20 0.40
CYP2C19 P33261 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8520737 0.86 ACP3 (0.53) ACP3TDP1SRCCYP1A2L3MBTL1
SCHEMBL8048486 0.82 ACP3 (0.49) ACP3TDP1SRCCYP1A2L3MBTL1
SCHEMBL7639813 0.81 ACP3 (0.48) ACP3TDP1SRCCYP1A2L3MBTL1
SCHEMBL915751 0.79 ACP3 (0.65) ACP3TDP1CYP1A2L3MBTL1CYP2C19
SCHEMBL31688391 0.79 ACP3 (0.65) ACP3TDP1CYP1A2L3MBTL1CYP2C19
SCHEMBL31587574 0.78 ACP3 (1.00) ACP3TDP1CYP1A2L3MBTL1CTNNB1
SCHEMBL233333 0.78 ACP3 (1.00) ACP3TDP1CYP1A2L3MBTL1CTNNB1
SCHEMBL8938051 0.78 ACP3 (0.58) ACP3TDP1SLC1A3SLC1A2SLC1A1
SCHEMBL20710776 0.77 ACP3 (0.49) ACP3TDP1CYP1A2L3MBTL1CYP2C19
SCHEMBL7609680 0.75 FAAH (0.49) TDP1L3MBTL1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002514184-A 2002-05-14 JP claimed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP claimed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO claimed